All News
ICYMI: Glucocorticoids-free zone in SLE?
For over 70 years, glucocorticoids, (GC) have been a part of standard therapy in SLE. They are classically used to not only induce remission or treat an acute flare, but also as maintenance therapy. They are a valuable 'friend' if used wisely, and can become a 'foe' if used excessively.
Read Article
ICYMI: SpA Sleuths: The Case of Undiagnosed IBD
Abstract #0494 provides context to our continual search for better understanding of inflammatory bowel disease in patients with AS, nr-AxSpA, and PsA.
Read Article
CBT or Naltrexone in Fibromyalgia (12.8.2023)
Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com. Be sure to catch the early registration break for 2024 RheumNow Live.
Read Article
FDA Warning on CAR-T Cell Therapy
On Nov. 28, 2024, FDA issued a safety alert regarding CAR-T cell immunotherapies; noting reports of T-cell malignancies (CAR-positive lymphoma) arising in patients treated with BCMA- or CD19-directed autologous CAR T cell immunotherapies and that if there is a risk, this only applies to currently approved BCMA-directed and CD19-directed genetically modified autologous CAR T cell immunotherapies.
Read Article
ICYMI: Are Rheumatologists doing Enough for Cervical Cancer?
Should rheumatologists be counseling patients on cervical cancer prevention and screening?
Read Article
ICYMI: How early is early in PsA?
Guidelines for the management of PsA recommend the early referral of patients with the suspected condition for early assessment and treatment.
https://t.co/9d6WONarwL https://t.co/lNNKzblkEP
Dr. John Cush RheumNow ( View Tweet)
Arthritis & Rheumatology has published a new study that suggests knee or hip osteoarthritis patients who are overweight or obese may have less premature death if slow to moderate rate of weight loss results from anti-obesity medications.
https://t.co/eSwcybRmX5 https://t.co/xEzMwIvAsK
Dr. John Cush RheumNow ( View Tweet)
ICYMI: Who gives a ‘JAK’ why and how they work, as long as they do!
https://t.co/dXp0bDlnMW https://t.co/k0Jl7EX6zt
Dr. John Cush RheumNow ( View Tweet)
Subtype of dermatomyositis is positive for Melanoma differentiation-associated protein 5 (MDA5) antibody. This poor prognosis subtype has distinctive rashes, rapidly progressive interstitial lung disease, lymphopenia &elevated ferritin levels https://t.co/30S4si0Luy https://t.co/xlEVEJMoSp
Dr. John Cush RheumNow ( View Tweet)
Cardiac Troponin T and MACE Events in RA
Dr. Arthur Kavanaugh discusses abstract 0387 at the 2023 ACR Convergence meeting in San Diego, CA.
https://t.co/6ZcIQzsv4n https://t.co/34fFk3HTWy
Dr. John Cush RheumNow ( View Tweet)
According to AAMC, clinical neurophysiology has lowest (0.8) number of MDs/100K, while pediatrics has the highest (59.5). In a list of 52, Rheumatology is #17 at mean of 2 Rheums per 100,000 population https://t.co/BrrfSIeHb9 https://t.co/69kRSlk9Dq
Dr. John Cush RheumNow ( View Tweet)
ICYMI: The Fallacy of Biologic Treatment to Prevent Rheumatoid Arthritis
The window of opportunity concept in RA then shifted our focus to trying to treat disease earlier and more aggressively to improve long term outcomes.
https://t.co/NTjYbMJJb6 https://t.co/TYuY1Q11xZ
Dr. John Cush RheumNow ( View Tweet)
Venous Thromboembolic Risk with Joint Replacement Save
A recent study suggests that thromboprophylaxis strategies should be tailored to individual risk of thrombosis and bleeding.
https://t.co/FKOsNkWMqz https://t.co/XH4SiQ735g
Dr. John Cush RheumNow ( View Tweet)
ICYMI: New Biomarkers and Therapeutics Show Potential in Still's Disease
AOSD is a rare complex, sporadic, systemic autoinflammatory disease similar to sJIA characterized by sustained fever, salmon-colored rash, and arthritis .
https://t.co/ZU0XFecPyP https://t.co/GLPsf73Hj0
Dr. John Cush RheumNow ( View Tweet)
Kuwait #RA registry study - shows in RA, the Uric acid level is inversely proportional to RA disease activity. 1054 RA pts, 15% had high UA level; lower DAS28 score associated w/ higher UA (p=0.032) OR 1.39; but higher HAQ assoc w/ higher UA https://t.co/muN0BFDs2Z https://t.co/VMdCgGPwPB
Links:
Dr. John Cush RheumNow ( View Tweet)
Early bird pricing has been extended! Register today!
https://t.co/xvGZgXxRs8 https://t.co/kiXk3TEvnD
Links:
Dr. John Cush RheumNow ( View Tweet)
Palmoplantar pustulosis (PPP) is difficult to treat; w/ few reports of JAKi efficacy. Now a report of 21 PPP pts given bimekizumab and 17 patients showed complete clearance in 1 to 4 months. SAPHO pts had complete clearance of skin & improved joint pain https://t.co/aHEiXZJGD8 https://t.co/QOuf8nsBXW
Dr. John Cush RheumNow ( View Tweet)
UK Dermatology Registry of 13 699 Psoriasis pts on biologics (25K biologic exposures) found 1% risk of paradoxical eczema. Biologics included inhibitors of TNF, IL-17, IL12/23, IL-23. Lowest risk w/ IL-23i (0.56/100kPY), and higher w/ IL-17i (1.22) https://t.co/SorkOl5G0J https://t.co/msNSJ0l9M4
Dr. John Cush RheumNow ( View Tweet)
Systematic review (3 studies) RA pts shows bariatric surgery (n=6700) can significantly lower disease activity at 12 mos and reduce comorbidities (OR=0.45) and in-hospital mortality (OR=0.41). BMI at baseline and after BS was 43.1 & 29.7kg/m2, respectively https://t.co/3Uweb5spGC https://t.co/2TAA2ppZpy
Dr. John Cush RheumNow ( View Tweet)
RCT 114 fibromyalgia pts Rx w/ cognitive behavioral Tx (CBT) vs control education. CBT had significant reduction in pain catastrophizing, pain interference & Sxs w/ improved function; neuroimaging in 98 pts also showed comparable improvement https://t.co/bKwREZdDF0 https://t.co/XkZJAMBfld
Dr. John Cush RheumNow ( View Tweet)